Collectively, our current study not only manifested that PODXL may serve as an independent prognostic indicator for GC, but also revealed a novel KLF4/PODXL signaling pathway in GC, which may be a promising molecular target for the treatment of GC. This evidence concerns the gene KLF4 and gastric cancer.